Thyroid medicine recalled nationwide: FDA

The U.S. Food and Drug Administration has announced a nationwide recall of a widely used thyroid medication due to concerns over its potency. Major Pharmaceuticals voluntarily initiated the recall after determining that the drug, Levothyroxine Sodium Tablets, was subpotent, meaning it did not contain the full amount of active ingredient required for therapeutic effectiveness. The recall was officially designated a Class II on July 17, indicating that while the product may cause temporary adverse health effects, it does not pose a serious or life-threatening risk. The affected medication is used to treat hypothyroidism and goiter, according to the Mayo Clinic. It is one of the most commonly prescribed medications in the United States, with millions of patients relying on it to manage thyroid hormone levels. The recall affects all batches of Levothyroxine Sodium Tablets produced by Major Pharmaceuticals, which were distributed nationally through both direct sales and third-party distributors. Cardinal Health, a major pharmaceutical distribution company, also played a role in distributing some of the recalled products. The recalled tablets were packaged in 10-count blister packs, either sold individually or in cartons containing 10 packs, totaling 100 tablets per box. They were available in six different dosage strengths: 25, 50, 75, 88, 112, and 150 micrograms. Each package bore an expiration date ranging from July 2026 to January 2027. While the FDA did not specify how many tablets were involved in the recall, it confirmed that the action was taken on July 13, following internal quality control assessments. Patients who have been using the recalled medication should contact their healthcare provider immediately to discuss alternative treatment options. The FDA advises individuals to check the lot numbers and expiration dates of their medication and to stop using the recalled product until further notice. A list of affected lots will be posted on the FDA’s website, along with instructions for returning unused medication to pharmacies or manufacturers. Major Pharmaceuticals has issued a statement acknowledging the recall and expressing regret for any inconvenience caused to patients. The company has pledged to work closely with regulatory authorities to ensure the safety and efficacy of its products moving forward. Meanwhile, Cardinal Health has also released a statement confirming its involvement in the distribution of the recalled medication and reaffirming its commitment to patient safety. Healthcare professionals are being urged to monitor patients closely during the transition period and to provide guidance on proper medication management. The incident highlights the importance of ongoing quality assurance processes in pharmaceutical manufacturing and underscores the need for robust systems to detect and address potential issues before they affect public health. As investigations into the root causes of the subpotency continue, the focus remains on ensuring that patients receive safe and effective treatments.